# Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

> **NCT04882085** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 60 (actual)

## Conditions studied

- Urinary Tract Infection
- Acute Pyelonephritis
- Hospital Acquired Pneumonia
- Ventilator-associated Pneumonia
- Bacteremia
- Intra-abdominal Infection

## Interventions

- **DRUG:** Zavicefta, Ceftazidime-Avibactam
- **DRUG:** Best Available Treatment

## Key facts

- **NCT ID:** NCT04882085
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-26
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882085, "Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04882085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*